Moxetumomab pasudotox-tdfk

{
  "id": "MLC-T-ONC-015295",
  "term": "Moxetumomab pasudotox-tdfk",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Moxetumomab pasudotox-tdfk exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.",
  "synonyms": [
    "moxetumomab pasudotox",
    "immunotoxin CAT-8015",
    "anti-CD22 immunotoxin CAT-8015"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/moxetumomab-pasudotox-tdfk/"
}